6I3U
Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models
6I3U の概要
エントリーDOI | 10.2210/pdb6i3u/pdb |
分子名称 | Phosphatidylinositol 3-kinase catalytic subunit type 3, 2-morpholin-4-yl-6-[7-[(2~{R})-1-morpholin-4-ylpropan-2-yl]oxy-9~{H}-thioxanthen-4-yl]pyran-4-one (3 entities in total) |
機能のキーワード | atm surrogate, vps34, kinase, huntington's disease, lyase |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 70641.74 |
構造登録者 | |
主引用文献 | Toledo-Sherman, L.,Breccia, P.,Cachope, R.,Bate, J.R.,Angulo-Herrera, I.,Wishart, G.,Matthews, K.L.,Martin, S.L.,Cox, H.C.,McAllister, G.,Penrose, S.D.,Vater, H.,Esmieu, W.,Van de Poel, A.,Van de Bospoort, R.,Strijbosch, A.,Lamers, M.,Leonard, P.,Jarvis, R.E.,Blackaby, W.,Barnes, K.,Eznarriaga, M.,Dowler, S.,Smith, G.D.,Fischer, D.F.,Lazari, O.,Yates, D.,Rose, M.,Jang, S.W.,Munoz-Sanjuan, I.,Dominguez, C. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models. J.Med.Chem., 62:2988-3008, 2019 Cited by PubMed: 30840447DOI: 10.1021/acs.jmedchem.8b01819 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.09 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード